Volume 345:618-619 August 23, 2001 Number 8
Cutaneous Reactions to STI571
To the Editor: The remarkable effects of the
tyrosine kinase inhibitor STI571 in chronic myeloid leukemia and
acute lymphoblastic leukemia reported by Druker et al. (April 5
issue)1,2 are frequently
associated with adverse cutaneous reactions. The rash was described
in only two patients — as "exfoliative dermatitis" in one and
as a "persistent and progressive rash" in the other.1,2 We recently
observed a severe adverse cutaneous reaction in a patient with
chronic myeloid leukemia who was treated with STI571; it was an acute
generalized exanthematous pustulosis, a well-characterized cutaneous
reaction to drugs.3,4 Interestingly,
the scarlatiniform erythema with nonfollicular pustules was
confined to flexural areas; such a pattern is often seen in
skin reactions to mercury.3 Mercury interferes with some
tyrosine kinases.3 As shown in Table 1, which was compiled from
published reports,1,2,3,5 the incidence of cutaneous
reactions to STI571 appears to be dose-dependent. This might indicate
that they are related to the pharmacologic effect of the drug rather
than to hypersensitivity.
Michel Brouard, M.D., Ph.D. Jean-Hilaire Saurat, M.D.
University Hospital CH-1211 Geneva, Switzerland mcvpb@hotmail.com
References
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a
specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med 2001;344:1031-1037.
- Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific
inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic
myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia
chromosome. N Engl J Med 2001;344:1038-1042.
- Brouard M, Prins C, Mach-Pascual S, Saurat JH. Acute generalized
exanthematous pustulosis associated with STI571 in a patient with chronic
myeloid leukemia. Dermatology (in press).
- Roujeau JC, Bioulac-Sage P, Bourseau C, et al. Acute generalized
exanthematous pustulosis: analysis of 63 cases. Arch Dermatol
1991;127:1333-1338.
- Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the
tyrosine kinase inhibitor STI571 in a patient with a metastatic
gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
Give me a holler
CMLSupport Home Page
This site was last updated on Sept. 1, 2001
Copyright © 2000-2001 CMLSupport.com. All rights reserved.
The fine print: These contents may not be reproduced in whole or in part without the express written permission of the author. Or she will beat you up and stuff. This site is best viewed with Internet Explorer, but we won't stop you from using another Web browser. Congratulations if you've read all of this! (But we're sorry to say, the person before you got our last cash prize!)
|